Manufacturing News of Note–GlaxoSmithKline strikes a deal for manufacturing T cells

Inn this week's news of note stories about GlaxoSmithKline, Samsung and Recipharm. (Pixabay)

> GlaxoSmithKline has struck a deal with Hitachi Chemical Advanced Therapeutics Solutions to manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials. Release

> Recipharm has completed its $60 million buyout of Sanofi’s contract inhalation drug business and plant in the U.K. Release

> South Korean CDMO Samsung BioLogics has started production of its Plant 3, what it is referring to as the world’s largest single bio manufacturing plant. Release